The biopharmaceutical company Vidac Pharma is inspiring new confidence among investors and millions of patients undergoing oncology treatment. As a clinical-stage company, it is developing therapies that target cancer cells by reversing their aberrant metabolism – a trick that tumors use to survive. The compounds in Vidac's pipeline, such as VDA-1102 and VDA-1275, attack cancer cells where they differ from healthy cells: they use excessive sugar for energy – a phenomenon discovered by Nobel Prize winner Otto Warburg (Warburg effect). These approaches from Vidac Pharma boost the immune response and could enhance the effect of other therapies when used in combination.
News & Events